Halofuginone inhibits tumorigenic progression of 5-FU-resistant human colorectal cancer HCT-15/FU cells by targeting miR-132-3p in vitro

5-Fluorouracil (5-FU)-based chemotherapy is the first-line option for patients with advanced colorectal cancer (CRC). However, the development of chemoresistance is the primary cause of treatment failure. Halofuginone (HF), a small molecule alkaloid derived from febrifugine, has been demonstrated to...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chen, Zhu, Jian-Bin, Yan, Yan-Yan, Zhang, Wei, Gong, Xiao-Jie, Wang, Xia, Wang, Xiao-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607966/
https://www.ncbi.nlm.nih.gov/pubmed/33154782
http://dx.doi.org/10.3892/ol.2020.12248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607966/
https://www.ncbi.nlm.nih.gov/pubmed/33154782
http://dx.doi.org/10.3892/ol.2020.12248

Ejemplares similares